Allosteric modulator potentiates β2AR agonist–promoted bronchoprotection in asthma models
Open Access
- 15 September 2023
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (18)
Abstract
Asthma is a chronic inflammatory disease associated with episodic airway narrowing. Inhaled β2-adrenergic receptor (β2AR) agonists (β2-agonists) promote — with limited efficacy — bronchodilation in asthma. All β2-agonists are canonical orthosteric ligands that bind the same site as endogenous epinephrine. We recently isolated a β2AR-selective positive allosteric modulator (PAM), compound-6 (Cmpd-6), which binds outside of the orthosteric site and modulates orthosteric ligand functions. With the emerging therapeutic potential of G-protein coupled receptor allosteric ligands, we investigated the impact of Cmpd-6 on β2AR-mediated bronchoprotection. Consistent with our findings using human β2ARs, Cmpd-6 allosterically potentiated β2-agonist binding to guinea pig β2ARs and downstream signaling of β2ARs. In contrast, Cmpd-6 had no such effect on murine β2ARs, which lack a crucial amino acid in the Cmpd-6 allosteric binding site. Importantly, Cmpd-6 enhanced β2 agonist–mediated bronchoprotection against methacholine-induced bronchoconstriction in guinea pig lung slices, but — in line with the binding studies — not in mice. Moreover, Cmpd-6 robustly potentiated β2 agonist–mediated bronchoprotection against allergen-induced airway constriction in lung slices obtained from a guinea pig model of allergic asthma. Cmpd-6 similarly enhanced β2 agonist–mediated bronchoprotection against methacholine-induced bronchoconstriction in human lung slices. Our results highlight the potential of β2AR-selective PAMs in the treatment of airway narrowing in asthma and other obstructive respiratory diseases.Keywords
Funding Information
- Howard Hughes Medical Institute (No number is available.)
- NIH (R01-HL016037)
- NIH (R01-AI110007, R01-AI161296)
- Integra Connect Grant (No number is available.)
This publication has 61 references indexed in Scilit:
- Chronic treatment in vivo with β‐adrenoceptor agonists induces dysfunction of airway β2‐adrenoceptors and exacerbates lung inflammation in miceBritish Journal of Pharmacology, 2011
- Distinct Phosphorylation Sites on the β2-Adrenergic Receptor Establish a Barcode That Encodes Differential Functions of β-ArrestinScience Signaling, 2011
- The cAMP-responsive Rap1 Guanine Nucleotide Exchange Factor, Epac, Induces Smooth Muscle Relaxation by Down-regulation of RhoA ActivityJournal of Biological Chemistry, 2011
- Agonist-Directed Desensitization of the β2-Adrenergic ReceptorPLOS ONE, 2011
- New perspectives regarding β2‐adrenoceptor ligands in the treatment of asthmaBritish Journal of Pharmacology, 2011
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLOS Biology, 2010
- β‐Arrestins specifically constrain β2‐adrenergic receptor signaling and function in airway smooth muscleThe FASEB Journal, 2008
- The genetic design of signaling cascades to record receptor activationProceedings of the National Academy of Sciences, 2008
- A guinea pig model of acute and chronic asthma using permanently instrumented and unrestrained animalsNature Protocols, 2006
- Circulating catecholamines in acute asthma.BMJ, 1985